Pharmanutra S.p.a.MIL: PHN

H1 2025 financial results

· Issued by Pharmanutra S.p.a.
H1_2025 FINANCIAL RESULTS

Sep 8th, 2025



HIGHLIGHTS H1 2025


4

HIGHLIGHTS
  • The results as of June 30, 2025, confirm, once again, a solid trend of organic growth in revenue with an increase of 10,4% compared to the same period of the previous year.

  • The contribution of new projects to revenues, although increased, remains marginal, while the associated development costs (around €4 million) have led to the anticipated limited reduction in operating margin.

  • The Net Financial Position as of June 30, 2025, is negative (-€5.1 million), compared to the positive balance of €5.6 million as of December 31, 2024 due to dividends distribution, Akern's earn out payment and working capital dynamics.





ECONOMIC AND FINANCIAL DATA


Attention: This is an excerpt of the original content. To continue reading it, access the original document here.